• The prevalence of Obesity and related comorbidities is increasing globally. Further among those comorbidities Diabetes, CVD, PCOS and NAFLD are most commonly observed
  • Limited therapeutic options, adverse effects of available treatments and dearth of prevention strategies pose many challenges
  • Evaluation of the efficacy of herbal drugs, neutraceuticals and lifestyle interventions for these conditions and elucidation of their mechanism of action forms our main objective
PCOS
NAFLD
Learning Memory Impairment
CVD
177 Milion by 2023

OBESITY

Mechanical & Psychological Stress
Hormonal Imbalance
Microbial dysbiosis
Insulin resistance
Inflammation
Oxidative stres
Impaired Glucose Tolerance
Free Fatty Acid
366 Milion by 2030

DIABETES